Hunan To Cut Essential Drug Prices By 30 Percent Next Year
This article was originally published in PharmAsia News
All public healthcare institutes in Hunan will sell essential drugs strictly at the provincial government's centralized drug bidding prices next year, cutting prices by an average of 30.3 percent according to statistics from Hunan's provincial price bureau
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.